Page 1

I - MAB BIOPHARMA I - Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization December 20 , 2021 - New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu , an internationally renowned oncologist , appointed as President and board director to lead the Company's R & D organization , focusing on global pipeline development - Founder and Chairman Dr. Jingwu Zang named Acting Chief Executive Officer - Newly established Commercialization Executive Council to catalyze corporate development and partnership deals for commercialization - I - Mab to host a call for investors on December 21 , 2021 , at 8:00 a.m. ET SHANGHAI , China and GAITHERSBURG , Md . , Dec. 20 , 2021 / PRNewswire / -- I - Mab ( the " Company " ) ( Nasdaq : IMAB ) , a clinical - stage biopharmaceutical company committed to the discovery , development , and commercialization of novel biologics , today announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company . The announcement is an integral part of I - Mab's strategic growth plans to position the Company for the next phase of development . I - MAB BIOPHARMA Dr. Andrew Zhu , an internationally renowned oncologist , joined I - Mab as President and board director to lead the Company's global R & D organization , focusing on delivering the pipeline milestones and enhancing clinical development capability in the U.S. and China . With his rich experience in global drug development , Dr. Zhu has worked with numerous pharmaceutical companies , including Merck , Eli Lilly , Roche , and Bayer . He has led and participated in more than 50 global clinical trials . Dr. Zhu will be based in Shanghai and report directly to company Founder and Chairman Dr. Jingwu Zang . " We're excited to welcome Dr. Zhu to I - Mab . Dr. Zhu is an established and world - renowned expert in clinical oncology with an impressive track record in clinical research and clinical development of novel drugs . As I - Mab's pipeline has reached a critical proof - of - concept and registrational stage , Dr. Zhu's deep clinical research expertise and novel drug development experience at the world's top academic institutions will be key to ensuring that we deliver the planned clinical milestones successfully and further enhance our competitive position in the global field of immuno - oncology , " Dr. Zang commented . " As a truly global biotech company with a rich and innovative pipeline , I - Mab has accomplished remarkable achievements within a short period of time . I am very excited to take on this role at I - Mab where I can effectively invest my passion and oncology expertise in leading the R & D team to the next level of clinical development capability and competitiveness and accelerating the delivery of I - Mab's global innovative clinical compounds to patients in need around the world , " said Dr. Zhu . Previously , Dr. Zhu served as a member of I - Mab's Scientific Advisory Board . To better prepare the transition towards the next phase of development , the Board has appointed Dr. Jingwu Zang , Founder and Chairman of I - Mab , as Acting Chief Executive Officer , effective January 1 , 2022. Dr. Zang founded I - Mab Biopharma and has served as Chairman and CEO since 2016 ( remaining as Chairman since October 2019 ) . Under his vision and leadership , the Company has set an ambitious agenda to focus on innovation in immuno - oncology and has rapidly emerged as an innovative clinical stage biotech with globally competitive assets , such as lemzoparlimab ( CD47 antibody ) , uliledlimab ( CD73 antibody ) and plonmarlimab ( GM - CSF antibody ) , which are now among the global front - runners . " Within a short period of time , I - Mab has evolved to become a significant global player in immuno - oncology field with a global reputation for its pursuit of first - in - class and best - in - class therapies . We trust that Dr. Zang will continue to help propel the Company to new levels and ensure a successful